Syndax raises $6 million to support ENCORE 301 study in breast cancer

Aug 12 2010

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced that it has issued $6M in convertible notes and warrants to its Series A investors bringing the total investment to date to $55M. All current investors, including Domain Associates, MPM Capital, Avalon Ventures, Forward Ventures, Pappas Ventures and MC Life Sciences participated in the securities offering.

"Our investors continue to demonstrate strong support for Syndax," said Joanna Horobin, M.D., president and chief executive officer of Syndax. "As reported at ASCO, our Phase 2 program studying entinostat, a class I isoform selective HDACi in advanced and metastatic breast cancer continues to show promise. This funding will support the completion of ENCORE 301, a randomized placebo controlled study of Aromasin® (exemestane) with and without entinostat in ER + breast cancer patients and positions the company to advance towards late-stage trials. We are optimistic that this study will provide further evidence demonstrating the clinical benefit and tolerability of entinostat in combination with hormone therapy."  HDACi are an emerging class of epigenetic therapeutics with the potential to reprogram aberrant gene expression, affect multiple cancer pathways and overcome tumor cell resistance mechanisms.

SOURCE Syndax Pharmaceuticals, Inc.